Novel therapies for pancreatic adenocarcinoma

被引：24

作者：

Pino S.M. ^{[1
]}

Xiong H.Q. ^{[1
]}

McConkey D. ^{[1
]}

Abbruzzese J.L. ^{[1
]}

机构：

[1] Dept. of Gastrointest. Med. Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030

来源：

Current Gastroenterology Reports | 2004年 / 6卷 / 2期

关键词：

Epidermal Growth Factor Receptor; Gemcitabine; Celecoxib; Pancreatic Adenocarcinoma; Epidermal Growth Factor Receptor Expression;

D O I：

10.1007/s11894-004-0038-x

中图分类号：

学科分类号：

摘要：

Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. In this article we review the current status of investigations into several classes of agents: matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; epidermal growth factor receptor inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors; cyclooxygenase-2 inhibitors, and others. The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed. Copyright © 2004 by Current Science Inc.

引用

页码：119 / 125

页数：6

共 50 条

[1]

Jemal A., Murray T., Samuels A., Cancer statistics, 2003, CA Cancer J. Clin., 53, SUPPL. 1, pp. 5-26, (2003)

[2]

Neoptolemos J.P., Dunn J.A., Stocken D.D., Et al., Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomized controlled trial, Lancet, 358, pp. 1576-1585, (2001)

[3]

Abrams R.A., Lillemoe K.D., Plantadosi S., Continuing controversy over adjuvant therapy of pancreatic cancer, Lancet, 358, pp. 1565-1566, (2001)

[4]

Burris H.A., Moore M.J., Andersen J., Et al., Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomized trial, J. Clin. Oncol., 15, pp. 2403-2413, (1997)

[5]

Von Hoff D., Mahadevan D., Bearss D., New developments in the treatment of patients with pancreatic cancer, Clin. Oncol. Updates, 4, pp. 1-15, (2001)

[6]

Lohr M., Trautmann B., Gottler M., Et al., Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins, Br. J. Cancer, 69, pp. 144-151, (1994)

[7]

Sato H., Takino T., Okada Y., Et al., A matrix metalloproteinase expressed on the surface of invasive tumor cells, Nature, 370, pp. 61-65, (1994)

[8]

Bramhall S.R., Rosemurgy A., Brown P.D., Et al., Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial, J. Clin. Oncol., 19, pp. 3447-3455, (2001)

[9]

Bramhall S.R., Schulz J., Nemunaitis J., Et al., A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer, Br. J. Cancer, 87, SUPPL. 2, pp. 61-167, (2002)

[10]

Moore M.J., Hamm J., Dancey J., Et al., Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 129566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 21, pp. 3296-3302, (2003)

← 1 2 3 4 5 →